{
    "clinical_study": {
        "@rank": "153207", 
        "arm_group": [
            {
                "arm_group_label": "Febuxostat 40 mg IR", 
                "arm_group_type": "Active Comparator", 
                "description": "Febuxostat 40 mg Immediate Release (IR) over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months."
            }, 
            {
                "arm_group_label": "Febuxostat 80 mg IR", 
                "arm_group_type": "Active Comparator", 
                "description": "Febuxostat 80 mg IR over-encapsulated tablet, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months."
            }, 
            {
                "arm_group_label": "Febuxostat 40 mg XR", 
                "arm_group_type": "Experimental", 
                "description": "Febuxostat 40 mg Extended Release (XR) over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months."
            }, 
            {
                "arm_group_label": "Febuxostat 80 mg XR", 
                "arm_group_type": "Experimental", 
                "description": "Febuxostat 80 mg XR over-encapsulated capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Febuxostat placebo-matching capsule, orally, once daily, and colchicine 0.6 mg tablet, orally, every other day, or, naproxen 250 mg tablets, orally, twice a day and lansoprazole 15 mg capsule, orally once daily, for 3 months."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of febuxostat 40 mg\n      extended release (XR) and 80 mg XR in comparison with febuxostat 40 mg immediate release\n      (IR) and 80 mg IR, respectively, in gout participants with moderate renal impairment."
        }, 
        "brief_title": "Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Gout", 
            "Moderate Renal Impairment"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Gout", 
                "Renal Insufficiency"
            ]
        }, 
        "detailed_description": {
            "textblock": "The drug being tested in this study is called febuxostat. Febuxostat is being tested to\n      decrease and maintain serum urate in people who have gout with moderate renal impairment.\n      This study will look at serum urate levels in people who take febuxostat extended release\n      (XR) capsules compared to febuxostat immediate release (IR) capsules and placebo.\n\n      The study will enroll approximately 200 patients. Participants will be randomly assigned (by\n      chance, like flipping a coin) to one of the five treatment groups\u2014which will remain\n      undisclosed to the participant and study doctor during the study (unless there is an urgent\n      medical need):\n\n        -  Febuxostat 40 mg XR\n\n        -  Febuxostat 80 mg XR\n\n        -  Febuxostat 40 mg IR\n\n        -  Febuxostat 80 mg IR\n\n        -  Placebo (dummy inactive pill) - this is a tablet that looks like the study drug but has\n           no active ingredient.\n\n      All participants will be asked to take one capsule at the same time each day throughout the\n      study, and will be asked to call an interactive voice response system any time they are\n      having a gout flare up. In addition to study medication, participants will also take 0.6 mg\n      of colchicine every other day or naproxen 250 mg twice a day with lansoprazole 15 mg once a\n      day to prevent gout flare ups.\n\n      This multi-center trial will be conducted in the United States. The overall time to\n      participate in this study is up to approximately 4 months and participants will make up to 7\n      visits to the clinic."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. In the opinion of the investigator, the participant is capable of understanding and\n             complying with protocol requirements.\n\n          2. The participant or, when applicable, the participant's legally acceptable\n             representative signs and dates a written, informed consent form and any required\n             privacy authorization prior to the initiation of any study procedure.\n\n          3. Has a history or presence of gout defined as having one or more of the American\n             Rheumatism Association (ARA) criteria for the diagnosis of gout:\n\n               1. A tophus proven to contain urate crystals by chemical or polarized light\n                  microscopic means, AND/OR;\n\n               2. Characteristic urate crystals in the joint fluid, AND/OR;\n\n               3. History of at least 6 of the following clinical, laboratory, and x-ray\n                  phenomena:\n\n             i. more that one attack of acute arthritis, ii. maximum inflammation developed within\n             1 day, iii. monoarticular arthritis, iv. redness observed over joints, v. first\n             metatarsophalangeal joint painful or swollen, vi. unilateral first\n             metatarsophalangeal joint attack, vii. unilateral tarsal joint attack, viii. tophus\n             (proven or suspected), ix. Hyperuricemia, x. asymmetric swelling within a joint on\n             x-ray, xi. subcortical cysts without erosions on x-ray, xii.  joint fluid culture\n             negative for organisms during attack.\n\n          4. Is male or female at least 18 years of age, inclusive.\n\n          5. A female participant of childbearing potential who is sexually active with a\n             nonsterilized male partner agrees to use routinely adequate contraception from\n             signing of informed consent throughout the duration of the study.\n\n          6. Have a serum urate (sUA) level \u22658.0 mg/dL at the Day -4 Visit or at the retest visit.\n\n          7. Has an estimated Glomerular Filtration Rate (eGRF) [Modification of Diet in Renal\n             Disease (MDRD)] \u226530 mL/min and <60 mL/min at Screening visit (Day -21 for\n             participants on urate lowering therapy (ULT) and Day -4 for participants not on ULT)\n             or at the retest visit.\n\n          8. Has at least one gout flare within 12 months prior to Screening visit.\n\n        Exclusion Criteria:\n\n          1. Has received any investigational compound within 30 days prior to Screening.\n\n          2. Is an immediate family member, study site employee, or is in a dependant relationship\n             with a study site employee who is involved in conduct of this study (eg, spouse,\n             parent, child, sibling) or may consent under duress.\n\n          3. Is breastfeeding or pregnant.\n\n          4. Has secondary hyperuricemia (eg, due to myeloproliferative disorder).\n\n          5. Has a history of xanthinuria.\n\n          6. Has received ULT (ie, allopurinol, probenecid, etc.) within 20 days prior to Day\n             1/Randomization Visit.\n\n          7. Has a know hypersensitivity to febuxostat or any components of their formulation; has\n             a known hypersensitivity to naproxen, any other nonsteroidal anti-inflammatory drug\n             (NSAID), aspirin, lansoprazole, colchicine or any components in their formulation.\n\n          8. Has active peptic ulcer disease.\n\n          9. Has a history of cancer (other than basal cell carcinoma of the skin) within 5 years\n             prior to the Screening Visit.\n\n         10. Has alanine aminotransferase (ALT) and aspartate aminotransferase (AST) values >2 x\n             the upper limit of normal (ULN).\n\n         11. Has rheumatoid arthritis which requires treatment.\n\n         12. Has a significant medical condition and/or conditions that would interfere with the\n             treatment, safety, or compliance with the protocol.\n\n         13. Has experienced either a myocardial infarction (MI), stroke, hospitalized unstable\n             angina, cardiac or cerebrovascular revascularization procedure or hospitalized\n             transient ischemic attack (TIA).\n\n         14. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol\n             abuse within 5 years prior to the Screening visit. Participant consumes >14 alcoholic\n             beverages/week.\n\n         15. Has participated in another investigational study within the 30 days prior to the\n             Screening Visit.\n\n         16. Has a know history of infection with hepatitis B, hepatitis C, or human\n             immunodeficiency virus.\n\n         17. Is required to take excluded medications."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02128490", 
            "org_study_id": "FEB-XR_201", 
            "secondary_id": "U1111-1152-3942"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Febuxostat 40 mg IR", 
                    "Febuxostat 80 mg IR"
                ], 
                "description": "Febuxostat IR over-encapsulated tablets", 
                "intervention_name": "Febuxostat IR", 
                "intervention_type": "Drug", 
                "other_name": "Uloric"
            }, 
            {
                "arm_group_label": [
                    "Febuxostat 40 mg XR", 
                    "Febuxostat 80 mg XR"
                ], 
                "description": "Febuxostat over-encapsulated capsules", 
                "intervention_name": "Febuxostat XR", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Febuxostat IR and XR placebo-matching capsules", 
                "intervention_name": "Febuxostat placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Febuxostat 40 mg IR", 
                    "Febuxostat 80 mg IR", 
                    "Febuxostat 40 mg XR", 
                    "Febuxostat 80 mg XR", 
                    "Placebo"
                ], 
                "description": "Colchicine tablets", 
                "intervention_name": "Colchicine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Febuxostat 40 mg IR", 
                    "Febuxostat 80 mg IR", 
                    "Febuxostat 40 mg XR", 
                    "Febuxostat 80 mg XR", 
                    "Placebo"
                ], 
                "description": "Naproxen tablets", 
                "intervention_name": "Naproxen", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Febuxostat 40 mg IR", 
                    "Febuxostat 80 mg IR", 
                    "Febuxostat 40 mg XR", 
                    "Febuxostat 80 mg XR", 
                    "Placebo"
                ], 
                "description": "Lansoprazole capsules", 
                "intervention_name": "Lansoprazole", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Naproxen", 
                "Colchicine", 
                "Febuxostat", 
                "Lansoprazole"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Drug therapy", 
        "lastchanged_date": "April 29, 2014", 
        "number_of_arms": "5", 
        "official_title": "A Phase 2, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout and Moderate Renal Impairment", 
        "overall_contact": {
            "email": "medicalinformation@tpna.com", 
            "last_name": "Takeda Study Registration Call Center", 
            "phone": "800-778-2860"
        }, 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Medical Director Clinical Science", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of Participants with Serum Urate <5.0 mg/dL at Month 3", 
            "safety_issue": "No", 
            "time_frame": "Month 3"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02128490"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of Participants with at Least One Gout Flare Requiring Treatment", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Month 3"
            }, 
            {
                "measure": "Percentage of Participants with Serum Urate <6.0 mg/dL at month 3", 
                "safety_issue": "No", 
                "time_frame": "Month 3"
            }
        ], 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}